 Home > Biochemistry News > Biotechnology News > Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy

Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy

 Last Update: 2022-03-06
 Source: Internet
 Author: User

Tags

based

treatment data

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Arvinas announced today that it has published new data showing that bavdegalutamide (also known as ARV-110), a novel PROTAC protein degrader targeting the androgen receptor (AR), targets metastatic castration-resistant prostate cancer (mCRPC), Continue to provide evidence of antitumor activity and patient benefit

Bavdegalutamide is an AR-targeting PROTAC protein degrader that recruits E3 ubiquitin ligases to the vicinity of ARs, tags ARs with ubiquitin, and guides them for proteasomal degradation

The latest data shows:

The PSA50 rate of patients with AR T878X/H875Y mutant tumors was 46% (n=26)

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy, Plans to Launch Pivotal Clinical Trial

03-07

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy

Related Articles

Express Arvinas Announces Latest Results of Androgen Receptor PROTAC Therapy, Plans to Launch Pivotal Clinical Trial